Systemic combination chemotherapy and intrathecal chemotherapy markedly increased the
survival rate of children with ALL. In the past two decades, the use of minimal (measurable) …

Most patients with advanced malignancies are treated with severely toxic, first-line
chemotherapies. Personalized treatment strategies have led to improved patient outcomes …

Cure rates for acute lymphoblastic leukemia (ALL), the most common childhood cancer have
steadily improved over the past five decades. This is due to intensifying systemic therapy …

PURPOSE High hyperdiploidy, the largest and favorable subtype of childhood ALL, exhibits
significant biological and prognostic heterogeneity. However, factors contributing to the …

Although a great cure rate has been achieved for pediatric BCP-ALL, approximately 15% of
patients do not respond to conventional chemotherapy and experience disease relapse. A …

Sequencing of bulk tumor populations has improved genetic classification and risk
assessment of B-ALL, but does not directly examine intratumor heterogeneity or infer …

Leukemia can arise at various stages of the hematopoietic differentiation hierarchy, but the
impact of developmental arrest on drug sensitivity is unclear. Applying network-based …

PURPOSE Acute lymphoblastic leukemia (ALL) can occur across all age groups, with a
strikingly higher cure rate in children compared with adults. However, the pharmacological …

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the
uncontrolled proliferation of immature lymphoid cells. Over past decades, significant …

Refractoriness to initial chemotherapy and relapse after remission are the main obstacles to
curing T cell acute lymphoblastic leukemia (T-ALL). While tumor heterogeneity has been …